{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:55:32Z","timestamp":1789570532900,"version":"build-2803163510"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Melanocytic nevi, dysplastic nevi, and melanoma are all derived from the pigment-producing cells, namely melanocytes. Concerning the clinical spectrum, cutaneous melanoma is the most aggressive skin cancer with a low survival rate, while nevi are the most common benign lesions in the general population, and dysplastic nevi place in between nevi and melanoma. Ultraviolet (UV) radiation is a well-recognized extrinsic risk factor for all three. BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      is a well-recognized driver mutation that activates the RAS-BRAF-mitogen-activated protein kinase (MAPK) signaling pathway among 40%\u201360% of melanoma cases. Interestingly, BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      mutation is detected even more in acquired nevi, approximately 80%. However, in nevi, several tumor suppressors such as p53 and phosphatase and tensin homolog (PTEN) are intact, and senescence factors, including p15\n                      <jats:sup>INK4b<\/jats:sup>\n                      , p16\n                      <jats:sup>INK4a<\/jats:sup>\n                      , p19, and senescence-associated acidic \u03b2-galactosidase, are expressed, leading to cell senescence and cell cycle arrest. Although loss of p53 function is rarely found in melanoma, decreased or loss of PTEN with an activated PI3k\/Akt signaling pathway is common in nevi, which may abolish senescence status and allow further progression into dysplastic nevi or melanoma. At present, mouse models closely resembling human nevi are used for investigating these phenomena. Melanocortin 1 receptor deficiency, an intrinsic risk factor for melanomagenesis, is related to the production of procarcinogenic pheomelanin and the inhibition of PTEN function. Immune response escape via programmed cell death-1\/programmed cell death ligand-1 interaction plays further roles in monitoring the spectrum. Here, we review the current literature on the molecular and immune mechanisms involving the transition from benign nevi to malignant melanoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_158_20","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T07:06:26Z","timestamp":1640761586000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Nevi, dysplastic nevi, and melanoma"],"prefix":"10.4103","volume":"34","author":[{"given":"Wei-Wen","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240828","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R2-1-20240828","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/ds.ds_13_19","article-title":"Cutaneous malignant melanoma in Eastern Taiwan: Clinicopathologic analysis of 56 cases","volume":"37","author":"Tsai","year":"2019","journal-title":"Dermatologica Sinica"},{"key":"R3-1-20240828","first-page":"15","article-title":"The ABCDEF Rule: Combining the \u201cABCDE rule\u201d and the \u201cugly duckling sign\u201d in an effort to improve patient self-screening examinations","volume":"8","author":"Daniel Jensen","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"R4-1-20240828","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.292.22.2771","article-title":"Early diagnosis of cutaneous melanoma: Revisiting the ABCD criteria","volume":"292","author":"Abbasi","year":"2004","journal-title":"JAMA"},{"key":"R5-1-20240828","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.134.7.845","article-title":"Ultraviolet radiation of melanocytic nevi: A dermoscopic study","volume":"134","author":"Hofmann-Wellenhof","year":"1998","journal-title":"Arch Dermatol"},{"key":"R6-1-20240828","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R7-1-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R8-1-20240828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fgene.2016.00095","article-title":"Melanocortin 1 receptor: Structure, function, and regulation","volume":"7","author":"Wolf Horrell","year":"2016","journal-title":"Front Genet"},{"key":"R9-1-20240828","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1006\/bbrc.2001.4429","article-title":"Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist","volume":"281","author":"Fr\u00e4ndberg","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"R10-1-20240828","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.molcel.2013.08.010","article-title":"MC1R is a potent regulator of PTEN after UV exposure in melanocytes","volume":"51","author":"Cao","year":"2013","journal-title":"Mol Cell"},{"key":"R11-1-20240828","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair\/fair skin background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"key":"R12-1-20240828","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/jid.2010.242","article-title":"Association between the germline MC1R variants and somatic BRAF\/NRAS mutations in melanoma tumors","volume":"130","author":"Scherer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R13-1-20240828","first-page":"1001","article-title":"Additional roles of A-MSH\/MC1R signaling in melanomagenesis beyond melanogenesis","volume":"1","author":"Dong","year":"2013","journal-title":"J Dermatolog Clin Res"},{"key":"R14-1-20240828","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf(V600E) cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"R15-1-20240828","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R16-1-20240828","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/carcin\/bgp337","article-title":"Targets of Raf in tumorigenesis","volume":"31","author":"Niault","year":"2010","journal-title":"Carcinogenesis"},{"key":"R17-1-20240828","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1248\/bpb.b13-00172","article-title":"Stem cell factor combined with matrix proteins regulates the attachment and migration of melanocyte precursors of human hair follicles in vitro","volume":"36","author":"Wang","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R18-1-20240828","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-1-20240828","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14740338.2015.1011618","article-title":"BRAF and MEK inhibition in melanoma","volume":"14","author":"Dossett","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R20-1-20240828","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/jid.2013.6","article-title":"Vemurafenib induces senescence features in melanoma cells","volume":"133","author":"Haferkamp","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R21-1-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/jidsymp.2009.6","article-title":"Progeroid syndromes and UV-induced oxidative DNA damage","volume":"14","author":"Kamenisch","year":"2009","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R22-1-20240828","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1039\/c2pp25275a","article-title":"A review of UVB-mediated photosensitivity disorders","volume":"12","author":"Kiss","year":"2013","journal-title":"Photochem Photobiol Sci"},{"key":"R23-1-20240828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ijc.2910550407","article-title":"Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma","volume":"55","author":"Castresana","year":"1993","journal-title":"Int J Cancer"},{"key":"R24-1-20240828","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1523-1747.2000.00877.x","article-title":"Mutation and allelic loss of the PTEN\/MMAC1 gene in primary and metastatic melanoma biopsies","volume":"114","author":"Birck","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R25-1-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/pcmr.12180","article-title":"Targeting p53 in melanoma","volume":"27","author":"Box","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"R26-1-20240828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"R27-1-20240828","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/nm.2863","article-title":"MDM4 is a key therapeutic target in cutaneous melanoma","volume":"18","author":"Gembarska","year":"2012","journal-title":"Nat Med"},{"key":"R28-1-20240828","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1755-148X.2010.00773.x","article-title":"p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation","volume":"23","author":"Terzian","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R29-1-20240828","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R30-1-20240828","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"R31-1-20240828","first-page":"3660","article-title":"Disruption of the MMAC1\/PTEN gene by deletion or mutation is a frequent event in malignant melanoma","volume":"57","author":"Guldberg","year":"1997","journal-title":"Cancer Res"},{"key":"R32-1-20240828","first-page":"1800","article-title":"Relative reciprocity of NRAS and PTEN\/MMAC1 alterations in cutaneous melanoma cell lines","volume":"60","author":"Tsao","year":"2000","journal-title":"Cancer Res"},{"key":"R33-1-20240828","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pcmr.12412","article-title":"Genetics of melanocytic nevi","volume":"28","author":"Roh","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"R34-1-20240828","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2133.2002.04748.x","article-title":"Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi","volume":"147","author":"Andreani","year":"2002","journal-title":"Br J DermatolW"},{"key":"R35-1-20240828","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bmt.2017.57","article-title":"Risk of melanocytic nevi and non-melanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Song","year":"2017","journal-title":"Bone Marrow Transplantation"},{"key":"R36-1-20240828","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17425255.2017.1247155","article-title":"Drug-induced eruptive melanocytic nevi","volume":"13","author":"Vena","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R37-1-20240828","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.cmr.0000222600.73179.f3","article-title":"BRAF and NRAS mutations in melanoma and melanocytic nevi","volume":"16","author":"Poynter","year":"2006","journal-title":"Melanoma Res"},{"key":"R38-1-20240828","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrc1884","article-title":"The power and the promise of oncogene-induced senescence markers","volume":"6","author":"Collado","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R39-1-20240828","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0046-8177(98)90019-3","article-title":"Enhanced expression of Ki-67, topoisomerase IIalpha, PCNA, p53 and p21WAF1\/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi","volume":"29","author":"Rudolph","year":"1998","journal-title":"Hum Pathol"},{"key":"R40-1-20240828","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/2159-8290.CD-15-0196","article-title":"CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma","volume":"5","author":"McNeal","year":"2015","journal-title":"Cancer Discov"},{"key":"R41-1-20240828","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J","article-title":"Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma","volume":"66","author":"Grob","year":"1990","journal-title":"Cancer"},{"key":"R42-1-20240828","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archderm.1991.01680060069006","article-title":"Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study","volume":"127","author":"Halpern","year":"1991","journal-title":"Arch Dermatol"},{"key":"R43-1-20240828","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.1997.03540420035026","article-title":"Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma","volume":"277","author":"Tucker","year":"1997","journal-title":"JAMA"},{"key":"R44-1-20240828","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0190-9622(87)70230-8","article-title":"Number of melanocytic nevi as a major risk factor for malignant melanoma","volume":"17","author":"Holly","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"R45-1-20240828","doi-asserted-by":"crossref","first-page":"19.e1","DOI":"10.1016\/j.jaad.2012.02.047","article-title":"The dysplastic nevus: From historical perspective to management in the modern era: Part II. Molecular aspects and clinical management","volume":"67","author":"Duffy","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R46-1-20240828","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.187252.112","article-title":"Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis","volume":"26","author":"Vredeveld","year":"2012","journal-title":"Genes Dev"},{"key":"R47-1-20240828","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","article-title":"Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases","volume":"23","author":"Dai","year":"2005","journal-title":"J Clin Oncol"},{"key":"R48-1-20240828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAT.0b013e328363b3bd","article-title":"Melanoma's connections to the tumour microenvironment","volume":"45","author":"Brandner","year":"2013","journal-title":"Pathology"},{"key":"R49-1-20240828","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R50-1-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"R51-1-20240828","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"R52-1-20240828","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"R53-1-20240828","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.jid.2015.11.035","article-title":"Discrimination of dysplastic nevi from common melanocytic nevi by cellular and molecular criteria","volume":"136","author":"Mitsui","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R55-1-20240828","doi-asserted-by":"crossref","first-page":"E8035","DOI":"10.1073\/pnas.1702763114","article-title":"CK1\u03b1 ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation","volume":"114","author":"Chang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_158_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:54Z","timestamp":1787755914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_158_20"}},"subtitle":["Molecular and immune mechanisms involving the progression"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_158_20","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}